REG - Allergy Therapeutics - Total Voting Rights

Allergy TherapeuticsAnnouncement

05/01/2022 08:50

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220105:nRSE4951Xa&default-theme=true

RNS Number : 4951X  Allergy Therapeutics PLC  05 January 2022

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Group")

Total Voting Rights

 

 

Allergy Therapeutics announces that pursuant to its block admission facility,
it has recently issued 1,798,428 ordinary shares of 0.1 pence each in the
capital of the company ("Ordinary Shares") in satisfaction of the exercise of
share options. The new Ordinary Shares rank pari passu with the Company's
existing shares.

In accordance with DTR 5.6.1 of the Financial Conduct Authority's Disclosure
Guidance and Transparency Rules, as at 4 January 2022, the Company has
643,597,146 Ordinary Shares in issue. There are no shares held in treasury.
The total number of voting rights in the Company is therefore 643,597,146.

The above figure of 643,597,146 may be used by shareholders in the Company as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change in their interest in, the
share capital of the Company under the FCA's Disclosure Guidance and
Transparency Rules.

 

For further information, please contact:

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

 

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

 

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / David Daley / Davide Salvi

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

 

Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

christina@sternir.com (mailto:christina@sternir.com)

 

 

 

Notes for editors:

About Allergy Therapeutics

 

Allergy Therapeutics is an international specialty pharmaceutical group
focussed on the treatment and diagnosis of allergic disorders, including
immunotherapy vaccines, that have the potential to cure disease. The Group
sells proprietary and third party products from its subsidiaries in nine major
European countries and via distribution agreements in an additional ten
countries. Its broad pipeline of products in clinical development include
vaccines for grass, tree and house dust mite, and peanut allergy vaccine in
pre-clinical development. Adjuvant systems to boost performance of vaccines
outside allergy are also in development.

 

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is
headquartered in Worthing, UK with more than 11,000m(2) of state-of-the-art
MHRA-approved manufacturing facilities and laboratories.  The Group, which
has achieved double digit compound annual growth since formation, employs
c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more
information, please see www.allergytherapeutics.com
(http://www.allergytherapeutics.com/) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVREAPFSELAAEEA